Stock PRAX PRAXIS PRECISION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
46.89 USD +0.64% Intraday chart for Praxis Precision Medicines, Inc. -12.17% +110.46%
Apr. 11 Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024. CI
Apr. 11 Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PRAXIS PRECISION MEDICINES TO PRESENT ON ULIXACALTAMIDE AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING
AQ
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
AQ
Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
CI
Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
CI
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
CI
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
MT
Praxis Precision Medicines to Participate in Upcoming April Conferences
AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Praxis Precision Medicines Prices $200 Million Public Offering
MT
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
AQ
Praxis Precision Medicines Plans Public Equity Offering
MT
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
AQ
Jefferies Adjusts Praxis Precision Medicines' Price Target to $128 From $75, Keeps Buy Rating
MT
Transcript : Praxis Precision Medicines, Inc. - Special Call
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
AQ
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients
CI
Praxis Precision Medicines to Host PRAX-628 Program Update
AQ
Praxis Precision Medicines Files $750 Million Mixed-Securities Shelf Registration
MT
Wedbush Adjusts Praxis Precision Medicines' Price Target to $41 From $29, Maintains Neutral Rating
MT
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRAX Stock
  4. News Praxis Precision Medicines, Inc.